Solving the problem of drug disposal

Size: px
Start display at page:

Download "Solving the problem of drug disposal"

Transcription

1 Solving the problem of drug disposal

2 Summary Why We Exist Who We Are To prevent the diversion of prescription opioids and to reinforce safe disposal of all medications through education and awareness A group of committed scientists and entrepreneurs who want to help solve the opioid abuse epidemic by establishing the gold standard for medication disposal What We Do How We Do It When Is It Available? Provide a unique cross-linking technology that is added to water which safely renders medications unusable and inconsumable. This is accomplished by using a proprietary blend of powders, which are a safe blend of chemical polymers listed by the FDA as safe and biodegradable By sharing with the consumer a technology that s as easy as adding a sweetener packet to iced tea or a flower food packet to a vase of flowers September 2017

3 Worst Drug epidemic in American History! Market is lacking non-toxic consumer facing medications disposal methods. Problem Purpose Raising awareness by highlighting safe and simple to use consumer facing medication disposal alternatives that captures unused medications in a non-toxic viscous environment, rendering it inaccessible removing it from the ecosystem of misuse, abuse & diversion. Goal Expand pharmacy services and educating patients with defined programs that mirror diabetes and hearth health initiatives, targeting the importance of proper medication disposal, through safe and cost-effective solutions.

4 Abuse Deterrent Experience John W. Holaday, Ph.D., is scientist with decades of experience in neuroscience, oncology and immunology. Dr. Holaday was the former CEO of QRxPharma Limited (QRX-ASX) and the co-founder of Medicis (MRX- NYSE) and served at the Walter Reed Army Institute of Research as Captain, US Army and Chair of Neuropharmacology Brand. Dr. Holaday holds a BS and MS from the University of Alabama, and PhD from the University of California, San Francisco School of Medicine. Edward Rudnic, Ph.D., is a scientist and pharmaceutical executive with an extensive background in the biopharmaceutical industry. Dr. Rudnic was founder, chairman and CEO of MiddleBrook Pharmaceuticals (Nasdaq: MBRK, previously Advancis; Nasdaq: AVNC) and was Sr. VP, Development and Technical Operations for Shire Laboratories, where he was the lead inventor of Carbatrol and co-inventor of Adderall XR. Dr. Rudnic has been named lead inventor or co-inventor of 54 issued U.S. patents and numerous related international patents. Dr. Rudnic holds a BS in Pharmacy, a MS in Pharmaceutics and a PhD in pharmaceutical Sciences from the University of Rhode Island. Marcus Schestopol, is a pharmaceutical development chemical engineer with over 15 years of experience in pharmaceutical CMC product development. Marcus received his Chemistry degree from Emory University and his Chemical Engineering degree from the Georgia Institute of Technology.

5 The Solution: DisposeRx TM 1: Open vial 2: Add warm tap water until vial is 2/3 full 3: Add DisposeRx Powder & shake for ~30 seconds, contents solidifies in <10 min. Pills + DisposeRx + Water = 100% effectiveness Proprietary, patented technology made of solidifying cross-linking chemical polymers to sequester all medications All materials used in DisposeRx are safe and listed in the FDA s Inactive Ingredient Database. DisposeRx crosslinking polymers are found in foods, oral drug products, are safe to ingest if accidentally exposed, and environmentally-friendly. Video Link:

6 DisposeRx Sequestration DisposeRx formulated testing Biodegradable matrix DisposeRx formulated its products to be compliant with evolving recommended governmental standards including DEA guidelines (Dec. 21, 2012, 21 CFR Subpart C, ). According to the DEA the method of destruction shall be consistent with the purpose of rendering all controlled substances to a non-retrievable state in order to prevent diversion of any such substance to illicit purposes and to protect the public health and safety.

7 Product Review At DisposeRx, our team is focused on stopping the opioid epidemic at the home medicine cabinet, preventing the cycle of environmental pollution, addiction, overdose and death. DisposeRx was designed especially for site-of-use disposal (the action of sequestering pharmaceutical ingredients within the vial in which the prescription was dispensed), uniquely capturing prescription drugs within the prescription vial, users are empowered with a best-in-class drug disposal solution. The disruptive cross-linking polymer blend, embraces safe and easy to understand user directions, providing the only prescription drug disposal solution which permanently captures drugs in a non-divertible and biodegradable gel. Our biodegradable solid is manufactured with components that are safe enough to be eaten. The disposal composition material, when combined with water and medicaments, forms a gel substance of high viscosity that it is not easily pourable, transferable, or mixable, and remains in the container in which it is formed. DisposeRx is able to provide homes and communities with a process where they can effortlessly be a part of the solution, breaking the chain of illicit prescription drug access and curbing our nation s opioid epidemic.

8 Extraction Data Data for all solvent extraction conditions are presented in this section. The mean percent (w/w) of Oxycodone recovered from the filtrate during each duplicate analyses was calculated and graphed. Specifically, the percent recovery of Oxycodone relative to the initial quantity of Oxycodone added was calculated (see Figure 1). Note: 40 tablets of 5 mg Oxycodone HCl equates to: 200 mg (0.200 g) Oxycodone HCl and mg ( g) Oxycodone free base. All results are reported as free base. A range of 0 8% of Oxycodone was recovered from filtrates across all conditions; this equates to approximately mg ( g) of Oxycodone. Gel after settling for minutes after mixing Test Product with water; white tablet particulate evident

9 Solvent Extraction Sample ID Oxycodone Added (mg) Filtrate Recovered (ml) Average Filtrate Recovered (ml) Oxycodone Recovered (mg) LC-MS/MS value (mcg/ml) Pre-filtration Mass (g) % Oxycodone Recovered Relative to Initial Oxycodone Added Average % Oxycodone Recovered Relative to Initial Oxycodone Added % Oxycodone Recovered Relative to Pre-filtration Mass Average % Oxycodone Recovered Relative to Pre-filtration Mass 1A B A B A % B A B A % % 5B % 6A % % 6B % 7A % % 7B % When considering the disposal of critical drugs of abuse including opioids (e.g. Oxycodone), it is essential that these substances are discarded in such a way that drug abusers are unable to access the material for abuse purposes. The DisposeRx product possesses multiple deterrence mechanisms which render the resulting material less amenable to abuse; these include the formation of a gelatinous mass upon mixing with pharmaceuticals, and the production of highly viscous solutions upon extracting the material with common household solvents. Sample preparation, Solvent extraction, Filtration and Quantitation data collected during study.

10 Thank you Wm Simpson, President 135 West Illinois Ave., Suite 1 Southern Pines, NC T/ (844) E/ wsimpson@disposerx.com

Disposal of leftover and expired drugs by sequestration in cross-linking. polymers

Disposal of leftover and expired drugs by sequestration in cross-linking. polymers Disposal of leftover and expired drugs by sequestration in cross-linking Introduction: polymers Marcus Schestopol and John Holaday, PhD DisposeRx, Inc., 6502 Hillmead Rd., Bethesda, MD 20817 Many medicaments,

More information

Copyright 2018 DisposeRx, Inc. All rights reserved.

Copyright 2018 DisposeRx, Inc. All rights reserved. 30 seconds breaks the chain of abuse and pollution!!! The problem starts at home; the solution: DisposeRx has developed a simple to use, inhome disposal solution for unused, unwanted, expired and/or off-therapy

More information

Reference ID: NDA was approved on December 12, The product was not formulated with properties to deter abuse,

Reference ID: NDA was approved on December 12, The product was not formulated with properties to deter abuse, tablets (NDA 020553). 1 According to Purdue, the reformulated OxyContin (OCR) had controlled-release features that would be less easily compromised by tampering than the original OxyContin (OC), and thereby

More information

Performance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)

Performance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q) Performance of North Carolina's System for Monitoring Prescription Drug Abuse Session Law 2015-241, Section 12F.16.(q) Report to the Joint Legislative Oversight Committee on Health and Human Services and

More information

Death, Detection, Diversion, & Disposal: Utah Case Study

Death, Detection, Diversion, & Disposal: Utah Case Study http://www.medicationdisposal.utah.gov/ ww.useonlyasdirected.org Death, Detection, Diversion, & Disposal: Utah Case Study Presented by: Erin Johnson, MPH, Utah Department of Health Elizabeth Sollis, CSW,

More information

SUBHEAD GOES HERE. Addressing Tennessee s Opioid Crisis. Natalie A. Tate, PharmD Vice President, Pharmacy

SUBHEAD GOES HERE. Addressing Tennessee s Opioid Crisis. Natalie A. Tate, PharmD Vice President, Pharmacy SUBHEAD GOES HERE Addressing Tennessee s Opioid Crisis Natalie A. Tate, PharmD Vice President, Pharmacy Our opioids story Our approach Our response to neonatal abstinence syndrome Facts and faces of opioid

More information

Michael M. Miller, MD, FASAM, FAPA

Michael M. Miller, MD, FASAM, FAPA Michael M. Miller, MD, FASAM, FAPA mmiller@rogershospital.org Medical Director, Herrington Recovery Center (HRC) Rogers Memorial Hospital Oconomowoc, Wisconsin Vice Speaker Wisconsin Medical Society Clinical

More information

Pennsylvania Prescription Drug Monitoring Program Trends,

Pennsylvania Prescription Drug Monitoring Program Trends, DEA Intelligence Report Brief DEA-PHL-DIR-006-17 Pennsylvania Prescription Drug Monitoring Program Trends, 2014-2015 December 2016 1 Executive Summary The abuse and diversion of pharmaceutical drugs, particularly

More information

Chairwoman Bono Mack, Vice-Chairwoman Blackburn, Ranking Member Butterfield and

Chairwoman Bono Mack, Vice-Chairwoman Blackburn, Ranking Member Butterfield and United States House of Representatives Committee on Energy and Commerce Subcommittee on Commerce, Manufacturing and Trade Hearing on Chairwoman Bono Mack, Vice-Chairwoman Blackburn, Ranking Member Butterfield

More information

Aligning Market Objectives and Policy for National Public Health

Aligning Market Objectives and Policy for National Public Health Abuse-Deterrent Formulations Summit March 7, 2017 Alexandria, Virginia Aligning Market Objectives and Policy for National Public Health Shruti Kulkarni, Esq. Outside Counsel Twitter: @claad_coalition CLAAD

More information

In Vitro Considerations for Development Abuse Deterrent Dosage Forms

In Vitro Considerations for Development Abuse Deterrent Dosage Forms In Vitro Considerations for Development Abuse Deterrent Dosage Forms Presentation to AAPS Annual Meeting Nov 3, 2014 Nagesh Bandi, Ph.D. Global CMC New Products Pfizer Inc. 1 Disclaimer The thoughts and

More information

Opioid Abuse in Iowa Rx to Heroin. Iowa Governor s Office of Drug Control Policy January 2016

Opioid Abuse in Iowa Rx to Heroin. Iowa Governor s Office of Drug Control Policy January 2016 1 Opioid Abuse in Iowa Rx to Heroin Iowa Governor s Office of Drug Control Policy January 2016 Why Is This Important? 2 3 National Rx Painkiller Trends CDC, 2013 4 National Rx-Heroin Trends NIH, 2015 5

More information

Egalet Corporate Presentation

Egalet Corporate Presentation Egalet Corporate Presentation Specialty Pharmaceutical Company Focused on Pain 1 NASDAQ: EGLT Forward-Looking Statements Statements included in this presentation that are not historical in nature are "forward-looking

More information

Rule Governing the Prescribing of Opioids for Pain

Rule Governing the Prescribing of Opioids for Pain Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This

More information

Naloxone and Combating the Opioid Epidemic

Naloxone and Combating the Opioid Epidemic Objectives Naloxone and Combating the Opioid Epidemic Jeff Jacobson PharmD Southpointe Pharmacy Discuss the current opioid crisis Define the role of Naloxone in opioid overdose Analyze the barriers to

More information

Proper Medication Disposal

Proper Medication Disposal Proper Medication Disposal MPhA 2014 Annual Conference September Disclosures I have no disclosures relative to this presentation. Carolyn O Donnell Minnesota Multistate Contracting Alliance for Pharmacy

More information

Naloxone Expanded Access: OTC status Considerations for a Nonprescription Drug Development Program

Naloxone Expanded Access: OTC status Considerations for a Nonprescription Drug Development Program Naloxone Expanded Access: OTC status Considerations for a Nonprescription Drug Development Program Andrea Leonard-Segal, M.D., M.S. Director, Division of Nonprescription Clinical Evaluation 1 Contents

More information

OXYCONTIN Diversion & Abuse Drug Enforcement Administration Office of Diversion Control October 2003

OXYCONTIN Diversion & Abuse Drug Enforcement Administration Office of Diversion Control October 2003 OXYCONTIN Diversion & Abuse Office of Diversion Control October 2003 OXYCONTIN OxyContin is a controlled release form of Schedule II oxycodone Manufactured in tablet form and intended for oral ingestion

More information

United States For Non-Dependence: An Analysis of the Impact of Opioid Overprescribing in America

United States For Non-Dependence: An Analysis of the Impact of Opioid Overprescribing in America United States For Non-Dependence: An Analysis of the Impact of Opioid Overprescribing in America September 26, 2017 USND Report Background This report is the culmination of research to identify and better

More information

How to inject op oxycontin

How to inject op oxycontin How to inject op oxycontin The Borg System is 100 % How to inject op oxycontin Injecting oxycontin is one of the primary methods of abusing this highly addictive prescription drug. Injecting oxycontin

More information

Doctor Shopping Behavior and the Diversion of Opioid Analgesics:

Doctor Shopping Behavior and the Diversion of Opioid Analgesics: Doctor Shopping Behavior and the Diversion of Opioid Analgesics: 2008-2012 A report prepared for The Executive Office of The President Office of National Drug Control Policy Ron Simeone Simeone Associates,

More information

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite

More information

ACCG Mental Health Summit

ACCG Mental Health Summit ACCG Mental Health Summit Sheila Pierce, Opioid Program Coordinator Director, Prescription Drug Management Program Discussion 1. Overview Opioid Problem in GA - Video 2. DPH Opioid Program 3. Priorities

More information

Our Core Thoughts on Dealing with the Opioid Addiction Crisis. Meghan McNelly, PharmD, MHA, FACHE Suzette Song, MD Joseph Alhadeff, MD

Our Core Thoughts on Dealing with the Opioid Addiction Crisis. Meghan McNelly, PharmD, MHA, FACHE Suzette Song, MD Joseph Alhadeff, MD Our Core Thoughts on Dealing with the Opioid Addiction Crisis Meghan McNelly, PharmD, MHA, FACHE Suzette Song, MD Joseph Alhadeff, MD Outline Brief History of the Opioid Problem How did we as a medical

More information

PREVENTION. Carroll County Health Department. Bureau of Prevention, Wellness and Recovery

PREVENTION. Carroll County Health Department. Bureau of Prevention, Wellness and Recovery PREVENTION Carroll County Health Department Bureau of Prevention, Wellness and Recovery What is Prevention? Prevention is the promotion of constructive lifestyles and norms that discourage drug abuse.

More information

Opioids drive continued increase in drug overdose deaths

Opioids drive continued increase in drug overdose deaths CDC: Drug overdose deaths increase for 11th consecutive year Opioids drive continued increase in drug overdose deaths Atlanta, GA, USA (February 20, 2013) - Drug overdose deaths increased for the 11th

More information

The Role of Dentists in Preventing Opioid Abuse Tufts Health Care Institute Program on Opioid Risk Management 12 th Summit Meeting March 11-12, 2010

The Role of Dentists in Preventing Opioid Abuse Tufts Health Care Institute Program on Opioid Risk Management 12 th Summit Meeting March 11-12, 2010 The Role of Dentists in Preventing Opioid Abuse Tufts Health Care Institute Program on Opioid Risk Management 12 th Summit Meeting March 11-12, 2010 EXECUTIVE SUMMARY It is well documented in multiple

More information

A LOOK AT ABUSE-DETERRENT OPIOIDS

A LOOK AT ABUSE-DETERRENT OPIOIDS JULY 2017 Drugs Under Review ICER s report reviewed evidence on ten abuse-deterrent formulations (ADF) of opioids. Nine of the drugs were extended release (ER) opioids, and one was immediate release (IR).

More information

Abuse of opioid painkillers in the US is a major problem

Abuse of opioid painkillers in the US is a major problem As appeared in January 2018 Tablets & Capsules www.tabletscapsules.com formulation Abuse-deterrent formulation technologies: Opportunities and limitations Alyn McNaughton Lonza Too many Americans are misusing

More information

THE FDA DRUG APPROVAL PROCESS Under the Federal Food, Drug, and Cosmetic (FD&C) Act, FDA is responsible for ensuring that all new drugs are safe and

THE FDA DRUG APPROVAL PROCESS Under the Federal Food, Drug, and Cosmetic (FD&C) Act, FDA is responsible for ensuring that all new drugs are safe and THE FDA DRUG APPROVAL PROCESS Under the Federal Food, Drug, and Cosmetic (FD&C) Act, FDA is responsible for ensuring that all new drugs are safe and effective. Before any drug is approved for marketing

More information

Understanding the US Opioid Analgesic Market

Understanding the US Opioid Analgesic Market Understanding the US Opioid Analgesic Market Key Trends & Market Snapshot December 2017 Purdue Pharma L.P. provided funding and content review for this report. Avalere Health maintained full editorial

More information

EXECUTIVE ORDER TAKING FURTHER ACTIONS TO ADDRESS THE OPIOID OVERDOSE CRISIS

EXECUTIVE ORDER TAKING FURTHER ACTIONS TO ADDRESS THE OPIOID OVERDOSE CRISIS EXECUTIVE ORDER TAKING FURTHER ACTIONS TO ADDRESS THE OPIOID OVERDOSE CRISIS Gina M. Raimondo, Governor Nicole Alexander-Scott, MD, MPH, Director of Health Action Plan Strategies to Date Since 2015, we

More information

The Challenge of Treating Pain

The Challenge of Treating Pain FDA Charge to the Committee: FDA Opioid Action Plan and Incorporating the Broader Public Health Impact into the Formal Risk-Benefit Assessment for Opioids Robert M. Califf, MD Commissioner of Food and

More information

Prescription Drug Safety for Teens

Prescription Drug Safety for Teens Prescription Drug Safety for Teens Curriculum Guide Recommended Grade Level 9-12 Total Time 30-45 minutes Subject Fit Health Standards Alignment National Health Education Standards (NHES) With prescription

More information

Schedules of Controlled Substances: Temporary Placement of Furanyl Fentanyl. AGENCY: Drug Enforcement Administration, Department of Justice

Schedules of Controlled Substances: Temporary Placement of Furanyl Fentanyl. AGENCY: Drug Enforcement Administration, Department of Justice This document is scheduled to be published in the Federal Register on 09/27/2016 and available online at https://federalregister.gov/d/2016-23183, and on FDsys.gov Billing Code 4410-09-P DEPARTMENT OF

More information

CSS Perspective - Opioid Risk Management

CSS Perspective - Opioid Risk Management Tufts Health Care Institute Program on Opioid Risk Management Risk Evaluation and Mitigation Strategy for Prescription Opioids: An In-Depth Review of Fundamental Issues CSS Perspective - Opioid Risk Management

More information

A National Perspective on the Abuse and Diversion of Prescription Drugs

A National Perspective on the Abuse and Diversion of Prescription Drugs A National Perspective on the Abuse and Diversion of Prescription Drugs Hilary L. Surratt, Ph.D Steven P. Kurtz, Ph.D. ARSH: Center for Applied Research on Substance Use and Health Disparities Faculty

More information

Regulating Physician Dispensing. Evidence From WCRI Studies

Regulating Physician Dispensing. Evidence From WCRI Studies Regulating Physician Dispensing Evidence From WCRI Studies Current Public Policies Most states permit physician dispensing 8 states physician dispensing rare or not allowed because of legal barriers Most

More information

FDA s Response to the Opioid Crisis and the FDA Safe Use Initiative

FDA s Response to the Opioid Crisis and the FDA Safe Use Initiative FDA s Response to the Opioid Crisis and the FDA Safe Use Initiative Scott K. Winiecki, MD Professional Affairs and Stakeholder Engagement Staff (PASES) Center For Drug Evaluation and Research (CDER) U.S.

More information

Education & Exhibit Center. Opening Eyes to Drugs: The Damaging Effects

Education & Exhibit Center. Opening Eyes to Drugs: The Damaging Effects Education & Exhibit Center Opening Eyes to Drugs: The Damaging Effects Letter from Gail and David Katz and Melissa Katz Gold Founding Directors, SAVE A STAR Drug Awareness Foundation The SAVE A STAR Drug

More information

Fentanyl, Opioid Overdose and Naloxone

Fentanyl, Opioid Overdose and Naloxone Fentanyl, Opioid Overdose and Naloxone Opioid Agonist Therapy Conference Saskatoon, SK April, 2016 Declaration No conflict of interest. Consultant in Addiction Medicine, SHR. Chair, College of Physicians

More information

Shining a Light on MEDs Understanding morphine equivalent dose

Shining a Light on MEDs Understanding morphine equivalent dose Shining a Light on MEDs Understanding morphine equivalent dose In the workers compensation industry, 60.2 percent of claimants utilize opioid analgesics for the treatment of pain caused by a workplace

More information

Land O Lakes Blvd S.R. 52. Veteran s Expy U.S Pasco Sheriff s Office (727) (West Operations Center) M-F 7432 Little Road

Land O Lakes Blvd S.R. 52. Veteran s Expy U.S Pasco Sheriff s Office (727) (West Operations Center) M-F 7432 Little Road Veteran s Expy Pasco County U.S. 19 Unused or expired medications are often flushed down a drain or end up in the wrong hands. Help protect our environment and the health of our community. Please dispose

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

What is drug diversion?

What is drug diversion? Learning Objectives Identify the impact of drug diversion on patients and healthcare organizations Explain the common points of risks and methods of drug diversion in healthcare s controlled substance

More information

Cardinal Health s Commitment to Opioid Anti-Diversion, Education and Misuse Prevention

Cardinal Health s Commitment to Opioid Anti-Diversion, Education and Misuse Prevention Cardinal Health s Commitment to Opioid Anti-Diversion, Education and Misuse Prevention The people of Cardinal Health care deeply about the devastation opioid abuse has caused American families and communities

More information

WHAT YOU NEED TO KNOW TO ABOUT AB 474

WHAT YOU NEED TO KNOW TO ABOUT AB 474 WHAT YOU NEED TO KNOW TO ABOUT AB 474 PRESENTED BY: NEVADA STATE BOARD OF OSTEOPATHIC MEDICINE 2275 Corporate Circle, Suite 210 Henderson, NV 89074 702-732-2147 Fax 702-732-2079 Web Site: www.bom.nv.gov

More information

Setting the Stage: Are Abuse-Deterrent Opioids Formulations Ready for Prime Time?

Setting the Stage: Are Abuse-Deterrent Opioids Formulations Ready for Prime Time? Setting the Stage: Are Abuse-Deterrent Opioids Formulations Ready for Prime Time? Lewis S. Nelson, MD New York University School of Medicine New York City Poison Control Center Opioid Abuse Liability

More information

Dan Cohen Forum Chair - Abuse DeterrentCoalition. Abuse Deterrent Formulations of Opioids and the Abuse Deterrent Coalition

Dan Cohen Forum Chair - Abuse DeterrentCoalition. Abuse Deterrent Formulations of Opioids and the Abuse Deterrent Coalition Dan Cohen Forum Chair - Abuse DeterrentCoalition Abuse Deterrent Formulations of Opioids and the Abuse Deterrent Coalition Prescription Drug Abuse and Diversion Partnering with Law Enforcement, Anti-Drug

More information

Prescription Drug Abuse National Perspective

Prescription Drug Abuse National Perspective Prescription Drug Abuse National Perspective Timothy P. Condon, Ph.D. Science Policy Advisor Office of the Director White House Office of National Drug Control Policy Commonly Abused Prescription Drugs

More information

Prescription Medication Guidelines for Medical Providers in CorVel s CorCare and Care IQ Networks

Prescription Medication Guidelines for Medical Providers in CorVel s CorCare and Care IQ Networks Prescription Medication Guidelines for Medical Providers in CorVel s CorCare and Care IQ Networks Patient Health and Safety Guidelines Prescription Medications Policy Update / April 2017 In connection

More information

Methadone. Description

Methadone. Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.41 Subject: Methadone Page: 1 of 8 Last Review Date: March 18, 2016 Methadone Description Dolophine

More information

Nucynta IR/ Nucynta ER (tapentadol immediate-release and extendedrelease)

Nucynta IR/ Nucynta ER (tapentadol immediate-release and extendedrelease) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Nucynta Page: 1 of 7 Last Review Date: March 18, 2016 Nucynta Description Nucynta IR/ Nucynta

More information

Strategies to Manage The Opioid Crisis

Strategies to Manage The Opioid Crisis Strategies to Manage The Opioid Crisis Matt Feehery, LCDC Senior Vice President & CEO PaRC (Prevention & Recovery Center) Behavioral Health Services February 1, 2018 A Pill for Your Pain But my doctor

More information

Safe Disposal in Colorado: A State-Led Approach

Safe Disposal in Colorado: A State-Led Approach Safe Disposal in Colorado: A State-Led Approach WELCOME! PDMP TTAC Webinar February 21, 2018 Safe Disposal in Colorado: A State-Led Approach Presenters Greg Fabisiak, Environmental Integration Coordinator,

More information

Appearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse

Appearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse Opening Statement Appearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse Dr. Chris Simpson, President-elect

More information

Safe Disposal of Unneeded Medications

Safe Disposal of Unneeded Medications Safe Disposal of Unneeded Medications Lesson created by: Marilyn Sink Molly Marshall Health & Human Sciences Educator/CED Health & Human Sciences Educator Clark County, Area 2 Jackson County, Area 2 msink@purdue.edu

More information

September 1, The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201

September 1, The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 September 1, 2017 The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Dear Secretary Price: The National Association of County

More information

Development of Abuse- Resistant Opioid Formulations

Development of Abuse- Resistant Opioid Formulations Development of Abuse- Resistant Opioid Formulations William K. Schmidt, PhD VP, Clinical Research, Renovis, Inc. Opioid Risk Management, March 29, 2005 Mrs Winslow's Soothing Syrup For children teething.

More information

Prescription Opioid Dependence and Addiction: Experience in the United States

Prescription Opioid Dependence and Addiction: Experience in the United States Prescription Opioid Dependence and Addiction: Experience in the United States September 27, 2013 Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center Professor, University of Colorado

More information

Documents Regarding Drug Abuse Assessments

Documents Regarding Drug Abuse Assessments Overview of the FDA Guidance Documents Regarding Drug Abuse Assessments ABUSE DETERRENT FORMULATION SCIENCE MEETING DISCUSSION OF THE FDA DRAFT GUIDANCE FOR INDUSTRY: ABUSE DETERRENT OPIOIDS EVALUATION

More information

Changes to the Eighth Edition

Changes to the Eighth Edition Pharmacy Practice and the Law, Eighth Edition Includes Navigate 2 Advantage Access By Richard R. Abood, BS Pharm, JD-Professor Emeritus Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences,

More information

The Difficult Patient: Risk Mitigation Strategies

The Difficult Patient: Risk Mitigation Strategies The Difficult Patient: Risk Mitigation Strategies C. Scott Anthony, D.O. Pain Management of Tulsa 1 Opioid Backlash National emergency Opioids not indicated for chronic pain Forces pushing for reduction

More information

INFORMATION BRIEF. Overview. Prescription Drug Abuse Among Young People

INFORMATION BRIEF. Overview. Prescription Drug Abuse Among Young People Product No. 2002-L0424-004 INFORMATION BRIEF AUGUST 2002 U. S. D E P A R T M E N T O F J U S T I C E Overview Prescription drugs, a category of psychotherapeutics that comprises prescription-type pain

More information

2004-L SEPTEMBER

2004-L SEPTEMBER BULLETIN INTELLIGENCE Buprenorphine: Potential for Abuse Product No. 2004-L0424-013 SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E NDIC Within the past 2 years buprenorphine a Schedule III

More information

Fundamentals of Pharmacology

Fundamentals of Pharmacology West Los Angeles College Worksheet #1 Fundamentals of Pharmacology Multiple Choice Identify the choice that best completes the statement or answers the question. 1. By which of the following routes are

More information

Guideline for the Rational Use of Controlled Drugs

Guideline for the Rational Use of Controlled Drugs Guideline for the Rational Use of Controlled Drugs Ministry of Health Male' Republic of Maldives April 2000 Table of Contents Page Introduction.. 2 1. Procurement and Supply of Controlled Drugs 3 1.1 Import

More information

Anyone Can Become Addicted. Anyone.

Anyone Can Become Addicted. Anyone. Anyone Can Become Addicted. Anyone. PAStop.org Family Toolkit Seeking Drug Abuse Treatment: Know What to Ask Trying to identify the right treatment programs for a loved one can be a difficult process.

More information

UNIVERSITY POLICY. Revised: Contact:

UNIVERSITY POLICY. Revised: Contact: UNIVERSITY POLICY Policy Name: Policy for Controlled Substances Section #: 90.2.3 Section Title: Compliance Approval Authority: Responsible Executive: Responsible Office: Formerly Book: President Adopted:

More information

Chapter 1: Fundamentals of Pharmacology Test Bank

Chapter 1: Fundamentals of Pharmacology Test Bank Chapter 1: Fundamentals of Pharmacology Test Bank MULTIPLE CHOICE 1. By which of the following routes are drugs administered directly into the bloodstream? a. Enteral b. Transdermal c. Transmucosal d.

More information

Introduction. Ethical Impact Analysis

Introduction. Ethical Impact Analysis Introduction As an ethical and responsible engineer, when designing any product, it is important to consider the impacts that it may have on its users and the world around us, both in normal use, and when

More information

Gabapentin diversion and misuse in the United States from a law enforcement perspective: Diversion rates and qualitative research findings

Gabapentin diversion and misuse in the United States from a law enforcement perspective: Diversion rates and qualitative research findings Gabapentin diversion and misuse in the United States from a law enforcement perspective: Diversion rates 2002-2015 and qualitative research findings Mance E. Buttram, PhD Steven P. Kurtz, PhD 2 nd European

More information

Prescription Drug Monitoring Program Update. Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017

Prescription Drug Monitoring Program Update. Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017 Prescription Drug Monitoring Program Update Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017 Objectives Brief historical overview of opioids Review of PDMP information Discuss ideas from

More information

EDUCATIONAL COMMENTARY METHADONE

EDUCATIONAL COMMENTARY METHADONE EDUCATIONAL COMMENTARY METHADONE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits see the Continuing Education

More information

STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A.

STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A. STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A. Arizona Corporate Counsel Presentation May 8, 2018 Agenda 1. Overview of the Opioid

More information

Ottawa Public Health Pam Oickle Sarah Archer

Ottawa Public Health Pam Oickle Sarah Archer Ottawa Public Health Pam Oickle Sarah Archer Pam Oickle Supervisor, Site Needle & Syringe Program Public Health Nurse 15 years Sarah Archer Public Health Nurse, Site Needle & Syringe Program 3 years Pamela.Oickle@Ottawa.ca

More information

GOVERNMENT S ROLE IN ADDRESSING PRESCRIPTION DRUG ABUSE

GOVERNMENT S ROLE IN ADDRESSING PRESCRIPTION DRUG ABUSE POSITION PAPER GOVERNMENT S ROLE IN ADDRESSING PRESCRIPTION DRUG ABUSE Governments across Canada are concerned about the abuse of prescription drugs, with recent policy discussions focused on mitigating

More information

Opioid Deaths Quadruple Since 1999

Opioid Deaths Quadruple Since 1999 THE COUNCIL OF STATE GOVERNMENTS CAPITOL RESEARCH AUGUST 2017 HEALTH POLICY Opioid Deaths Quadruple Since 1999 Since 1999, the number of overdose deaths involving opioids (including prescription opioids

More information

Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases

Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases Overview On August 2, 2017, U.S. Attorney General Jeff Sessions announced a pilot program whereby a new federal data analysis program is being

More information

NDA MF REMS ASSESSMENT ACKNOWLEDGMENT

NDA MF REMS ASSESSMENT ACKNOWLEDGMENT DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 REMS ASSESSMENT ACKNOWLEDGMENT Insys Development Co. c/o Insys Therapeutics, Inc. 1333 South Spectrum Blvd.,

More information

Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)

Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

PREVENTING OPIATE OVERDOSES IN SCHOOLS. Head 2 Toe 2017 April 20, 2017 Winona Stoltzfus BSN, MD, School Health Officer and Acting RHO SE Region

PREVENTING OPIATE OVERDOSES IN SCHOOLS. Head 2 Toe 2017 April 20, 2017 Winona Stoltzfus BSN, MD, School Health Officer and Acting RHO SE Region PREVENTING OPIATE OVERDOSES IN SCHOOLS Head 2 Toe 2017 April 20, 2017 Winona Stoltzfus BSN, MD, School Health Officer and Acting RHO SE Region WHY IS THIS EVEN A QUESTION FOR SCHOOLS? In 2014, 467,000

More information

On December 27, 2017, the Lieutenant Governor signed into law several new requirements

On December 27, 2017, the Lieutenant Governor signed into law several new requirements OPIOID Alert MICHIGAN OSTEOPATHIC ASSOCIATION JANUARY 2018 On December 27, 2017, the Lieutenant Governor signed into law several new requirements aimed at combating the opioid epidemic. On the following

More information

OPIOID SAFE- PRESCRIBING TRAINING IMMERSION (OSTI)

OPIOID SAFE- PRESCRIBING TRAINING IMMERSION (OSTI) OPIOID SAFE- PRESCRIBING TRAINING IMMERSION (OSTI) Case 1- Prep Materials University of Massachusetts Medical School Opioid Conscious Curriculum March 2018 Learner Prep Objectives The purpose of this prep

More information

Investors Update: Abuse-Deterrent d-amphetamine Immediate Release (ADAIR) for ADHD

Investors Update: Abuse-Deterrent d-amphetamine Immediate Release (ADAIR) for ADHD Investors Update: Abuse-Deterrent d-amphetamine Immediate Release (ADAIR) for ADHD February 7, 2017 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning

More information

Pharmaceutical Fentanyl s (PF) Role in Fentanyl- related Overdose Deaths

Pharmaceutical Fentanyl s (PF) Role in Fentanyl- related Overdose Deaths Pharmaceutical Fentanyl s (PF) Role in Fentanyl- related Overdose Deaths Paper presented at the 2018 annual meetings of the American Public Health Association, San Diego, CA Session 5061.0: Impact of fentanyl

More information

Titan Pharmaceuticals Overview

Titan Pharmaceuticals Overview Corporate Presentation July 2014 1 Safe Harbor The presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities

More information

OVERVIEW OF PRESENTATION

OVERVIEW OF PRESENTATION OVERVIEW OF PRESENTATION Trends Methodology Key messages from public consultation Vision Values, Goals, s Performance Measurement System Health-led actions Structures supporting delivery DRUG AND ALCOHOL

More information

Changing Prescribing Practices In Dentistry

Changing Prescribing Practices In Dentistry Changing Prescribing Practices In Dentistry Paul J. Desjardins, D.M.D., Ph.D. Adjunct Clinical Professor, Rutgers School of Dental Medicine Visiting Professor, Tufts University, School of Dental Medicine

More information

Online Appendix. Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids

Online Appendix. Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids Online Appendix Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids Abby Alpert, David Powell, Rosalie Liccardo Pacula Appendix Figure A.1:

More information

Prescription Drug Monitoring Program (PDMP)

Prescription Drug Monitoring Program (PDMP) Prescription Drug Monitoring Program (PDMP) District of Columbia Information contained in this presentation is accurate as of September 2017 Meet the Speaker Tadessa Harper-Nichols Program Specialist Pharmaceutical

More information

Safe Medication Disposal A white position paper Pennsylvania Pharmacists Association February 8, 2009

Safe Medication Disposal A white position paper Pennsylvania Pharmacists Association February 8, 2009 Safe Medication Disposal A white position paper Pennsylvania Pharmacists Association February 8, 2009 Background and Situation Analysis: Consumers are rightly confused about what to do with their unwanted

More information

Media Kit. September 2017

Media Kit. September 2017 Media Kit September 2017 About Pear Pear Therapeutics is the leader in FDA-cleared Prescription Digital Therapeutics. The company s approach is to integrate clinically-validated software applications with

More information

Addiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer

Addiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South

More information

WORKING UPSTREAM TO COMBAT THE OPIOID CRISIS

WORKING UPSTREAM TO COMBAT THE OPIOID CRISIS WORKING UPSTREAM TO COMBAT THE OPIOID CRISIS WELCOME Kate Gainer, PharmD Executive Vice President and CEO Iowa Pharmacy Association PRESENTER Sarah Derr, PharmD Medication Management Lead Iowa Healthcare

More information

Trends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville

Trends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville Trends and Challenges: The Kentucky Opioid Crisis Jason Smith, MD PhD University of Louisville Brief Introduction I am by no means an expert I have no financial disclosures Jokes are meant to be lighthearted

More information

FORMULATION DEVELOPMENT - A QbD Approach to Develop Extended Release Softgels

FORMULATION DEVELOPMENT - A QbD Approach to Develop Extended Release Softgels Seite 1 von 8 Share this story: Issue: April 2015, Posted Date: 3/30/2015 FORMULATION DEVELOPMENT - A QbD Approach to Develop Extended Release Softgels INTRODUCTION Soft gelatin capsules (softgels) continue

More information

9/3/2013. Presentation Objective. Prescription Drug Abuse Statistics Prescription Drug Abuse Statistics. Pharmaceutical Drugs and the Environment

9/3/2013. Presentation Objective. Prescription Drug Abuse Statistics Prescription Drug Abuse Statistics. Pharmaceutical Drugs and the Environment Presentation Objective Background - Why do we need a regulation for the disposal of controlled substances. Disposal of Controlled Substances DEA Notice of Proposed Rulemaking AHMP 2013 National Conference

More information

Opioid Policy Steering Committee: Prescribing Intervention--Exploring a Strategy for

Opioid Policy Steering Committee: Prescribing Intervention--Exploring a Strategy for This document is scheduled to be published in the Federal Register on 12/13/2017 and available online at https://federalregister.gov/d/2017-26785, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

2016 Drug Trends Series

2016 Drug Trends Series Drug Trends Series Part 3: Assessing opioids and compounds Published August 2017 1 Drug Trends Series Opioids & Compounds First Script Introduction As with the first two editions in Coventry s Drug Trends

More information